



Dyve Biosciences Will Present Study Data During the Aesthetics Innovation Summit and The Aesthetic Meeting

CEO Ryan Beal, MD to discuss clinical program results in melasma

May 13, 2019 – Thousand Oaks, California – Dyve Biosciences, a biotech drug delivery company developing breakthrough platform technology that broadly enables transdermal drug delivery, announced it will present data from its human proof-of-concept trial at the Aesthetics Innovation Summit 2019, held May 15, and The Aesthetic Meeting 2019, held May 16 – 21. Both meetings will take place in New Orleans.

For the audience of physicians and industry leaders at these key meetings, Dyve Biosciences Co-Founder and CEO Ryan Beal, MD will discuss the company's advanced clinical programs for treatment of melasma. The presentations will highlight current data on Dyve's investigational technology, DYV-600, as well as provide an overview of Dyve's novel transdermal delivery technology. DYV-600 delivers tranexamic acid deep into the skin to dramatically reduce skin pigmentation for those with melasma.

"More than half of women have melasma after childbirth. Current options are limited to lasers or topicals that provide only modest efficacy or have safety concerns," Dr. Beal said. "Based on early research of tranexamic acid, we were prompted to study it in combination with our transdermal drug delivery technology. Our human proof-of-concept trial demonstrates how we can modulate our technology to optimize transdermal drug delivery and offer patients an effective option to injections, oral drugs, or ineffective topicals. We believe this has the potential of being a game changer in the treatment of hyperpigmentation."

Aesthetics Innovation Summit 2019

- **Host:** Industry and investment leaders and media
- **Presentation:** Morning Innovation Showcase: Breakthrough Transdermal Delivery of Tranexamic Acid for the Improved Management of Melasma
- **Date and time:** Wednesday, May 15, 9:24 – 9:31 a.m. CDT

The Aesthetic Meeting 2019

- **Host:** American Society for Aesthetic Plastic Surgery and the Aesthetic Surgery Education and Research Foundation
- **Theme:** Premier Global Hot Topics
- **Presentation:** Getting Under Your Skin – New Developments in Skin Science: Finding Unexpected Beauty in Aesthetic Innovation



- **Date and time:** Friday, May 17, 5:31 p.m. CDT

About Dyve Biosciences

Dyve Biosciences created a breakthrough platform technology that broadly enables transdermal drug delivery. Dyve's novel transdermal delivery technology improves the safety, efficacy and ease of use of existing drugs through the skin. The company has advanced clinical programs in gout and melasma and is rapidly developing a strong pipeline across a broad range of therapeutic areas. At Dyve, the focus is on robust science, compelling data and delivering positive patient outcomes. For more information please visit www.dyvebio.com.

Contact

Amy Phillips

Pascale

C: 412.327.9499

amy@pascalecommunications.com

###